Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QTTB Stock Forecast 2026-2027
$5.72
Current Price
$83.83M
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to QTTB Price Targets
+249.7%
To High Target of $20.00
+127.3%
To Median Target of $13.00
+74.8%
To Low Target of $10.00
QTTB Price Momentum
+13.3%
1 Week Change
-6.7%
1 Month Change
+169.8%
1 Year Change
+72.3%
Year-to-Date Change
-28.9%
From 52W High of $8.05
+325.3%
From 52W Low of $1.35
📊 TOP ANALYST CALLS
Did QTTB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Q32 Bio is one of their latest high-conviction picks.
Latest QTTB Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, QTTB has a bullish consensus with a median price target of $13.00 (ranging from $10.00 to $20.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $5.72, the median forecast implies a 127.3% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Christopher Raymond at Piper Sandler, projecting a 249.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QTTB Analyst Ratings
2
Buy
1
Hold
0
Sell
QTTB Price Target Range
Low
$10.00
Average
$13.00
High
$20.00
Current: $5.72
Latest QTTB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QTTB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 25, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Initiates | $13.00 |
| Mar 12, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $15.00 |
| Feb 11, 2025 | Piper Sandler | Christopher Raymond | Neutral | Downgrade | $4.00 |
| Feb 11, 2025 | BMO Capital | Etzer Darout | Market Perform | Downgrade | $3.00 |
| Dec 12, 2024 | BMO Capital | Etzer Darout | Outperform | Maintains | $22.00 |
| Dec 12, 2024 | Guggenheim | Yatin Suneja | Neutral | Downgrade | $N/A |
| Dec 11, 2024 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $20.00 |
| Dec 11, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $16.00 |
| Dec 11, 2024 | Raymond James | Steven Seedhouse | Outperform | Downgrade | $22.00 |
| Dec 11, 2024 | Oppenheimer | Jay Olson | Outperform | Maintains | $20.00 |
| Dec 11, 2024 | Leerink Partners | Thomas Smith | Market Perform | Downgrade | $9.00 |
| Dec 6, 2024 | BMO Capital | Etzer Darout | Outperform | Initiates | $64.00 |
| Oct 24, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Initiates | $90.00 |
| Sep 11, 2024 | Wells Fargo | Sarah Akers | Overweight | Initiates | $95.00 |
| Jun 17, 2024 | Guggenheim | Yatin Suneja | Buy | Initiates | $100.00 |
| May 21, 2024 | Leerink Partners | Thomas Smith | Outperform | Initiates | $54.00 |
| Apr 11, 2024 | Oppenheimer | Jay Olson | Outperform | Initiates | $50.00 |
| Apr 2, 2024 | Piper Sandler | Christopher Raymond | Overweight | Initiates | $45.00 |
Q32 Bio Inc. (QTTB) Competitors
The following stocks are similar to Q32 Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Q32 Bio Inc. (QTTB) Financial Data
Q32 Bio Inc. has a market capitalization of $83.83M with a P/E ratio of 2.4x. The company generates $53.74M in trailing twelve-month revenue with a 55.5% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of +85.4% and return on equity of +125.1%.
Valuation Metrics
Market Cap
$83.83M
Enterprise Value
$53.07M
P/E Ratio
2.4x
PEG Ratio
-1.1x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
+85.4%
Net Margin
+55.5%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+57.7%
Current Ratio
4.9x
Debt/Equity
36.5x
ROE
+125.1%
ROA
+13.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Q32 Bio Inc. (QTTB) Business Model
About Q32 Bio Inc.
What They Do
Develops biologic therapies for immune disorders.
Business Model
The company focuses on developing biologic therapeutics targeting immune regulation for autoimmune and inflammatory diseases. It generates revenue through the advancement of its drug candidates in clinical trials, with a notable focus on bempikibart (ADX-914) for alopecia areata and previous asset sales such as ADX-097 to Akebia Therapeutics.
Additional Information
Q32 Bio, founded in 2017 and based in Waltham, Massachusetts, is engaged in addressing unmet medical needs in immune-mediated conditions with its innovative antibody-based therapies. The company is currently in the Phase 2 clinical trial stage with its lead candidate, and it also retains other therapeutic platforms aimed at complement inhibition.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
42
CEO
Ms. Jodie Pope Morrison
Country
United States
IPO Year
N/A
Website
www.q32bio.comQ32 Bio Inc. (QTTB) Latest News & Analysis
Latest News
Quick Summary
Q32 Bio Inc. (Nasdaq: QTTB) will participate in a fireside chat on April 8, 2026, focusing on therapies for alopecia areata and other autoimmune diseases.
Why It Matters
Q32 Bio's participation in a public forum may indicate confidence in their progress and could influence investor sentiment, impacting stock performance and market interest in their therapies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Q32 Bio (QTTB) has a consensus price target indicating a 97.7% upside potential. Upward earnings estimate revisions suggest possible near-term stock gains.
Why It Matters
A 97.7% upside potential for Q32 Bio suggests significant growth opportunity, while rising earnings estimates may indicate positive momentum, attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Q32 Bio focuses on Bempikibart for alopecia areata, with mid-2026 topline data as a key catalyst. They sold ADX-097 to Akebia, gaining milestone and royalty payments.
Why It Matters
Q32 Bio's focus on Bempikibart's R&D and potential for durable responses in alopecia areata, along with milestone payments from ADX-097, could drive future valuation and investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
New Strong Buy Stocks for March 27th
21 days ago
Quick Summary
DNN, CM, MGY, QTTB, and FLXS received a Zacks Rank #1 (Strong Buy) designation on March 27, 2026.
Why It Matters
The addition of DNN, CM, MGY, QTTB, and FLXS to the Zacks Rank #1 (Strong Buy) indicates strong potential for stock performance, signaling favorable investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Best Momentum Stocks to Buy for March 27th
20 days ago
Quick Summary
MGY, ESCA, and QTTB are ranked as Zacks Rank #1 (Strong Buy) momentum stocks as of March 27, 2026.
Why It Matters
MGY, ESCA, and QTTB being ranked as Strong Buy indicates strong momentum and potential for price appreciation, signaling favorable investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Q32 Bio (QTTB) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects, which may lead to a potential stock price increase.
Why It Matters
Q32 Bio's upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and attracting buying interest, which can drive stock prices higher.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About QTTB Stock
What is Q32 Bio Inc.'s (QTTB) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Q32 Bio Inc. (QTTB) has a median price target of $13.00. The highest price target is $20.00 and the lowest is $10.00.
Is QTTB stock a good investment in 2026?
According to current analyst ratings, QTTB has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QTTB stock?
Wall Street analysts predict QTTB stock could reach $13.00 in the next 12 months. This represents a 127.3% increase from the current price of $5.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Q32 Bio Inc.'s business model?
The company focuses on developing biologic therapeutics targeting immune regulation for autoimmune and inflammatory diseases. It generates revenue through the advancement of its drug candidates in clinical trials, with a notable focus on bempikibart (ADX-914) for alopecia areata and previous asset sales such as ADX-097 to Akebia Therapeutics.
What is the highest forecasted price for QTTB Q32 Bio Inc.?
The highest price target for QTTB is $20.00 from Christopher Raymond at Piper Sandler, which represents a 249.7% increase from the current price of $5.72.
What is the lowest forecasted price for QTTB Q32 Bio Inc.?
The lowest price target for QTTB is $10.00 from at , which represents a 74.8% increase from the current price of $5.72.
What is the overall QTTB consensus from analysts for Q32 Bio Inc.?
The overall analyst consensus for QTTB is bullish. Out of 9 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are QTTB stock price projections?
Stock price projections, including those for Q32 Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 3:44 AM UTC